tiprankstipranks
Trending News
More News >
Beijing Airdoc Technology Co. Ltd. Class H (HK:2251)
:2251
Hong Kong Market

Beijing Airdoc Technology Co. Ltd. Class H (2251) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Beijing Airdoc Technology Co. Ltd. Class H

(2251)

Rating:49Neutral
Price Target:
HK$12.00
▼(-8.54%Downside)
Beijing Airdoc Technology Co. Ltd. faces significant financial and valuation challenges, with declining revenues, negative profitability, and concerning cash flow issues being the most significant factors. The technical analysis provides some neutral signals, but overall concerns outweigh any positive aspects. Strategic improvements are necessary to enhance financial stability and investor confidence.

Beijing Airdoc Technology Co. Ltd. Class H (2251) vs. iShares MSCI Hong Kong ETF (EWH)

Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model

Company DescriptionBeijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
How the Company Makes MoneyBeijing Airdoc Technology Co. Ltd. generates revenue primarily through the sale and licensing of its AI-powered diagnostic software and solutions to healthcare institutions, such as hospitals and clinics. The company offers software-as-a-service (SaaS) models, enabling clients to access its diagnostic tools via subscription. Additionally, Airdoc may engage in partnerships and collaborations with medical device manufacturers and healthcare providers to expand its market reach and integrate its technology into existing healthcare systems. Revenue is also driven by research and development collaborations, where Airdoc partners with academic institutions and pharmaceutical companies to enhance its AI algorithms and expand its capabilities into other medical fields.

Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview

Summary
Beijing Airdoc Technology Co. Ltd. faces significant financial challenges with declining revenues and persistent losses. Despite a strong equity base, the company struggles with operational inefficiencies and negative cash flows, posing serious risks to financial stability.
Income Statement
20
Very Negative
The company has experienced significant declines in revenue with a 23.35% decrease from 2023 to 2024. Gross profit margins remain relatively healthy at 55.42% in 2024, but net income is deeply negative, reflecting ongoing profitability challenges. The negative EBIT and EBITDA margins indicate operational inefficiencies and high costs relative to revenue.
Balance Sheet
35
Negative
The company maintains a strong equity position with an equity ratio of 89.87% in 2024, indicating low financial leverage. However, the negative return on equity reflects losses and underutilization of equity capital. Total liabilities remain low, which reduces financial risk, but persistent negative net income impacts overall financial health.
Cash Flow
15
Very Negative
The company's cash flows are concerning, with zero operating and free cash flow in 2024. The inability to generate positive cash flow from operations raises sustainability concerns. Historical cash flows have been volatile, with significant negative free cash flow, highlighting challenges in managing cash effectively.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue156.37M203.96M113.66M115.18M47.67M
Gross Profit86.68M125.13M55.85M70.24M29.09M
EBITDA-259.70M-113.36M-159.64M-126.73M-49.42M
Net Income-255.46M-132.53M-187.23M-136.99M-79.63M
Balance Sheet
Total Assets1.41B1.68B1.74B1.89B435.75M
Cash, Cash Equivalents and Short-Term Investments774.82M1.14B1.41B1.78B374.70M
Total Debt31.88M9.37M8.01M8.20M519.00K
Total Liabilities134.86M127.13M68.59M74.19M27.30M
Stockholders Equity1.27B1.54B1.67B1.82B408.21M
Cash Flow
Free Cash Flow-167.51M8.02M-392.55M-140.11M-64.77M
Operating Cash Flow-165.43M23.37M-380.44M-112.09M-42.86M
Investing Cash Flow-11.34M-385.14M-154.43M-22.01M91.69M
Financing Cash Flow-33.31M-18.53M-17.14M1.55B240.63M

Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.12
Price Trends
50DMA
12.25
Positive
100DMA
12.65
Positive
200DMA
12.03
Positive
Market Momentum
MACD
0.21
Negative
RSI
60.11
Neutral
STOCH
37.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2251, the sentiment is Positive. The current price of 13.12 is above the 20-day moving average (MA) of 12.33, above the 50-day MA of 12.25, and above the 200-day MA of 12.03, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 60.11 is Neutral, neither overbought nor oversold. The STOCH value of 37.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2251.

Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
HK$2.06B9.488.35%8.20%0.61%-15.89%
64
Neutral
¥338.68B10.99-2.99%2.58%11.79%-10.20%
52
Neutral
HK$2.32B33.92-7.51%1.09%-0.56%-323.09%
49
Neutral
HK$1.36B-18.19%-24.50%-93.44%
48
Neutral
HK$2.47B-48.48%0.50%-21.82%-700.17%
45
Neutral
HK$5.06B-2.97%11.00%56.87%
45
Neutral
HK$2.42B-75.64%42.21%29.52%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.02
-1.02
-7.26%
HK:2158
Yidu Tech, Inc.
5.57
1.96
54.29%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.93
0.15
5.40%
HK:2325
Yunkang Group Limited
3.98
-5.49
-57.97%
HK:3309
C-MER Eye Care Holdings Limited
1.85
-0.63
-25.40%
HK:3681
SinoMab Bioscience Ltd.
2.03
0.41
25.31%

Beijing Airdoc Technology Co. Ltd. Class H Corporate Events

Beijing Airdoc Technology Successfully Concludes 2024 AGM with All Resolutions Passed
Jun 27, 2025

Beijing Airdoc Technology Co., Ltd. announced that all resolutions proposed at its 2024 annual general meeting were duly passed by shareholders. The meeting was conducted in compliance with relevant legal and regulatory requirements, with all directors and supervisors in attendance, either physically or via telecommunication. The successful passing of resolutions indicates a smooth operational and governance process, potentially reinforcing stakeholder confidence in the company’s management and strategic direction.

Beijing Airdoc Technology Announces Board Composition and Roles
Jun 27, 2025

Beijing Airdoc Technology Co., Ltd. has announced the composition of its board of directors and their roles within various committees. This update reflects the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive edge and ensuring sustainable growth in the rapidly evolving medical technology industry.

Beijing Airdoc Completes H Share Full Circulation
Jun 13, 2025

Beijing Airdoc Technology Co., Ltd. announced the completion of its 2024 H Share Full Circulation, converting 50,151,012 Unlisted Shares into H Shares, which will be listed on the Stock Exchange of Hong Kong. This move marks a significant step in the company’s market operations, potentially enhancing its liquidity and accessibility for investors, thereby strengthening its position in the market.

Beijing Airdoc Technology Announces 2024 AGM with Key Resolutions
May 28, 2025

Beijing Airdoc Technology Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 27, 2025, where shareholders will consider various resolutions. These include approving the company’s 2024 reports, financial accounts, profit distribution plan, and the re-appointment of Ernst & Young as auditors. Additionally, the AGM will address the appointment of Mr. WEI Yubo as an executive director and the use of idle funds for cash management. Special resolutions will cover mandates for issuing new shares and repurchasing H shares. These resolutions are crucial for the company’s strategic financial management and governance, potentially impacting its market positioning and shareholder value.

Beijing Airdoc Technology Secures Approval for H Share Full Circulation
May 26, 2025

Beijing Airdoc Technology Co., Ltd. has received approval from the Stock Exchange for the listing and conversion of 50,151,012 H Shares as part of its 2024 H Share Full Circulation initiative. This development involves 26 participating shareholders and marks a significant step in the company’s expansion and market presence, potentially enhancing its liquidity and shareholder base.

Beijing Airdoc Announces Leadership Changes
May 26, 2025

Beijing Airdoc Technology Co., Ltd. announced the resignation of Mr. Wei Yubo as a supervisor due to an internal transfer within the company. Mr. Wei has been nominated for the position of executive director, pending shareholder approval at the upcoming annual general meeting. Additionally, Ms. Luo Yujie has been elected as an employee representative supervisor and chairman of the Board of Supervisors, bringing her extensive experience in auditing and internal control to the role.

Beijing Airdoc Gains CSRC Approval for H Share Circulation
Apr 28, 2025

Beijing Airdoc Technology Co., Ltd. has received approval from the China Securities Regulatory Commission (CSRC) for the full circulation of its domestic unlisted shares. This approval allows 26 shareholders to convert over 50 million unlisted shares into H shares, which can be listed and traded on the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, although further procedural steps are required before completion.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025